Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® ▼ (baricitinib)
Olumiant® ▼ (baricitinib): Major Adverse Cardiovascular Events in the Rheumatoid Arthritis Clinical Development Program
In the BARI clinical development program, treatment with BARI in patients with moderately to severely active RA was not associated with an increased risk of MACE.
Cardiovascular Risk in Patients With Rheumatoid Arthritis
Exclusion Criteria Related to Cardiovascular Events in the Baricitinib Rheumatoid Arthritis Clinical Development Program
In the 4 phase 3 clinical trials, RA-BEGIN, RA-BEAM, RA-BUILD, and RA-BEACON, eligibility criteria relating to CV events excluded patients who
have screening electrocardiogram abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the patient’s participation in the study, such as Fridericia’s corrected QT interval >500 milliseconds
within 12 weeks of study entry have experienced
unstable ischemic heart disease
have New York Heart Association stage IV heart failure.3
Cardiovascular Event Adjudication Process in Rheumatoid Arthritis Clinical Trials
An independent, external CEC was established to adjudicate potential CV adverse events for the BARI phase 3 clinical studies. The CEC remained blinded to treatment assignments and assessed each potential event individually.3
Potential CV events were identified to be sent for adjudication
by the investigator indicating that a potential event occurred, or
by sponsor and independent CEC review of SAE and TEAE MedDRA preferred terms according to a prespecified list to ensure that potential CV events that qualified for adjudication were sent for review.3
Positively adjudicated CV events were categorized as either
MACE, which included
other CV event, which included
All cases of death, regardless of the investigator’s assessment as to the cause of death, were also sent for adjudication.3
Integrated Datasets Used to Evaluate Major Adverse Cardiovascular Events in Rheumatoid Arthritis Clinical Trials
The integrated datasets used to evaluate cases of MACE are described in more detail in . The exposure information, including median, maximum and total PYE, and cut-off date described in the table is applicable to the data presented below unless otherwise specified.
7-Study Placebo-Controlled Dataset
Studies: JADC, JADA, JADN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BALANCE
Compares BARI 4 mg vs placebo
Includes patients with RA from 3 phase 2 and 4 phase 3 studies who were randomized to
BARI 4 mg (N=1142, [exposure through 24 weeks: PYE=471.8, median exposure=169 days, maximum exposure=211 days]), or
placebo (N=1215, [exposure through 24 weeks: PYE=450.8, median exposure=166 days, maximum exposure=235 days]).
Patients in the placebo group could have been taking
background MTX, or
in some studies, other conventional DMARD therapy.
Evaluation time periods included
through the 12-week placebo-controlled period in phase 2 studies
through 16 weeks of assigned treatment before any opportunity for rescue therapy in phase 3 studies, and
through 24 weeks of assigned treatment or until rescue in phase 3 studies.
BARI 2 mg Analysis Set
BARI 2 mg data is derived from 4 studies in which both BARI 2 mg (N=479, [exposure through 24 weeks: PYE=185.8, median exposure=168 days, maximum exposure=197 days]) and BARI 4 mg were options during randomization (JADA, JADN, RA-BUILD, RA-BEACON).
4-Study Extended Dataset
Studies: JADA, JADN, RA-BUILD, RA-BEACON, RA-BEYOND (extension)
Compares BARI 4 mg vs BARI 2 mg including extended evaluations
Includes patients with RA from 2 phase 2 and 2 phase 3 studies and any further exposure for those patients in the phase 3 extension study, RA-BEYOND, who were randomized to
BARI 4 mg (N=479, PYE=781.1, median exposure=342 days, maximum exposure=3085 days), or
BARI 2 mg (N=479, PYE=774.9, median exposure=257 days, maximum exposure=2370 days).
Evaluation time period included randomization through last available observation incorporating extension data through 01 September 2019 unless otherwise specified.
All BARI RA Dataset
Studies: JADB, JADC, JADA, JADN, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BALANCE, RA-BEYOND (extension)
No between-group comparisons
Includes patients with RA (N=3770, PYE=13,148, median exposure=4.2 yrs, maximum exposure=8.4 yrs) from 1 phase 1, 3 phase 2, 5 phase 3 studies, and 1 phase 3 extension study who received BARI at a variety of doses, including
BARI 4 mg (n=3400)
BARI 2 mg (n=1077), and
BARI 1 mg, 7 mg, 8 mg, and 10 mg QD doses not evaluated in confirmatory studies.
Patients had to have received at least 1 dose of BARI and could have received different doses throughout the trials.
Evaluation time period is all exposure time points including after rescue or changes in study drug through 01 September 2019 unless otherwise specified.
Abbreviations: BARI = baricitinib; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; PYE = patient-years of exposure; QD = once daily; RA = rheumatoid arthritis.
Incidence of Major Adverse Cardiovascular Events in the Baricitinib Rheumatoid Arthritis Clinical Development Program
Incidence rates were calculated as the number of patients with an event per 100 patient-years of exposure time, with exposure censored at time of event.6
7-Study Placebo-Controlled Dataset
In the combined 7-study dataset up to week 24, the number of patients with at least 1 positively adjudicated MACE was
3 (IR=0.7) in the BARI 4-mg group
0 in the BARI 2-mg group, and
2 (IR=0.5) in the placebo group.6
4-Study Extended Dataset
In the combined 4-study extended dataset, the number of patients with at least 1 positively adjudicated MACE was
3 (0.7%; EAIR=0.40) in the BARI 2-mg group, and
2 (0.5%; EAIR=0.29) in the BARI 4-mg group.3
All BARI RA Dataset
In the All BARI RA dataset, there were 63 MACE across all BARI doses and exposure durations. The incidence rate was 0.5 events per 100 PYE.5
Figure 1 displays the incidence rate for patients in the All BARI RA dataset with positively adjudicated MACE overall and by 12-month intervals. The rate of MACE does not appear to increase with duration of BARI exposure.7
Figure 1. Incidence Rate of Positively Adjudicated MACE by Time Periods in RA Clinical Studies7
1. Kume K, Amano K, Yamada S. AB0463 Tofacitinib improves arterial stiffness with methotrexate-resistant active rheumatoid arthritis: a cohort study [abstract]. Ann Rheum Dis. 2014;73(suppl 2):961. http://dx.doi.org/10.1136/annrheumdis-2014-eular.1019
2. Sen D, Gonzalez-Mayda M, Brasington RD, Jr. Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2014;40(1):27-49. http://dx.doi.org/10.1016/j.rdc.2013.10.005
4. Weinblatt M, Taylor PC, Burmester GR, et al. Cardiovascular safety – update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheumatol. 2018;70(suppl 10):2815. https://acrabstracts.org/abstract/cardiovascular-safety-update-from-up-to-6-years-of-treatment-with-baricitinib-in-rheumatoid-arthritis-clinical-trials/
5. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis [abstract]. Ann Rheum Dis. 2020;79(suppl 1):638. https://ard.bmj.com/content/79/Suppl_1/642.1
6. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020;2(6):E347-E357. https://doi.org/10.1016/S2665-9913(20)30032-1
7. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis. Poster presented at: European League Against Rheumatism Virtual Congress; June 3-6, 2020.
BARI = baricitinib
CEC = Clinical Endpoint Committee
CV = cardiovascular
EAIR = exposure-adjusted incidence rate
IR = incidence rate
IV = intravenous
MACE = major adverse cardiovascular event
MedDRA = Medical Dictionary for Regulatory Activities
MI = myocardial infarction
PYE = patient-years of exposure
RA = rheumatoid arthritis
SAE = serious adverse event
TEAE = treatment-emergent adverse event
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: September 01, 2020